Placeholder Banner

BIO Submits Comments on NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products

November 2, 2020

On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period in line with WTO recommendations in the future. BIO’s preliminary review is generally supportive of the guideline, commending China “for joining the growing number of countries preparing its regulatory system for the proliferation of these innovative therapies.” BIO was also pleased to note the document’s references to relevant ICH guidelines and applauded NMPA’s engagement in ICH, including on the Management Committee. BIO looks forward to the NMPA’s final guidance on the topic.

Download Full Comments Below
BIO Comments -CDE Cell Therapy Clinical Trial
Discover More
As you prepare for Chancellor Merkel’s visit to Washington, we, the representatives of America’s biotechnology sector thought that you and your government might benefit from an update on all that our sector is doing globally to address the ongoing…
We would like to provide you some updates on the U.S. and global biotechnology industry’s efforts to scale-up global vaccine production to address the global imbalance in access to COVID vaccines, and to request a close working relationship with…
The undersigned food, agriculture, and seafood trade associations respectfully urge the expeditious nomination of the Chief Agricultural Negotiator at the Office of the U.S. Trade Representative. America’s farmers, ranchers, processors, exporters…